Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Generate Biomedicines, Inc.NASDAQ: GENB

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) of 128.19M shares in Q1 FY2026

Q1 FY2026 weighted avg shares (diluted) was 128.19M shares.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
128.19M— QoQ
Last fiscal yearDec 2025
50.09M-60.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-60.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
50.09M USD
Year-over-year change
-60.7%
1-year CAGR
-60.7%

Weighted Avg Shares (Diluted) vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 weighted avg shares (diluted) of 50.09M shares is the 3rd highest of the 5 companies compared; the peer median is 79.62M shares.
  • Its year-over-year change of -60.7% is the lowest of 5, against a peer median of +3.0%.
GENB Competitors Peer median
Weighted Avg Shares (Diluted) for GENB and competitors
Company Period LTM YoY 3-year CAGR
ABCLAbCellera Biologics Inc.LTM Sep 2026306.35M +3.0%-1.7%
ABSIAbsci CorporationLTM Mar 2026143.73M +23.4%+14.6%
GENBGenerate Biomedicines, Inc.FY202550.09M -60.7%—
INBXInhibrx Biosciences, Inc.LTM Mar 202615.5M +3.0%-27.2%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding GENB) 79.62M+3.0%+6.4%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.46M31.89M
Cost of Revenue00
Gross Profit20.46M31.89M
Gross Margin100.0%100.0%
Research & Development175.31M224.7M
Selling, General & Admin42.09M42.26M
Operating Expenses217.4M266.96M
Depreciation & Amortization15.35M13.18M
EBITDA(163.71M)(208.49M)
EBITDA Margin-800.2%-653.7%
Operating Income(196.94M)(235.07M)
Operating Margin-962.6%-737.0%
Interest Income18.12M13.66M
Interest Expense2.12M1.14M
Other Income / Expenses15.77M12.26M
Income Before Tax(181.17M)(222.8M)
Pre-Tax Margin-885.5%-698.6%
Income Tax Expense212K163K
Net Income(173.77M)(203.15M)
Net Margin-849.4%-637.0%
EPS (Basic)(1.68)(4.98)
EPS (Diluted)(1.68)(4.98)
Weighted Avg Shares127.45M50.09M
Weighted Avg Shares (Diluted)127.45M50.09M

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.